Get the Stockscreener App
0.2983
2.71%
-0.0083
Ernexa Therapeutics Inc stock is traded at $0.2983, with a volume of 569.60K.
It is down -2.71% in the last 24 hours and down -56.13% over the past month.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
See More
Previous Close:
$0.3066
Open:
$0.31
24h Volume:
569.60K
Relative Volume:
0.58
Market Cap:
$8.08M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.0359
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
+0.10%
1M Performance:
-56.13%
6M Performance:
-76.23%
1Y Performance:
-93.02%
1-Day Range:
$0.294
$0.33
1-Week Range:
$0.2754
$0.33
52-Week Range:
$0.2682
$4.50
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
0.2983 | 8.30M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Ernexa Therapeutics Inc.Common Stock (NQ: ERNA - FinancialContent
Comparing Aditxt (NASDAQ:ADTX) & Ernexa Therapeutics (NASDAQ:ERNA) - Defense World
ERNA Technical Analysis & Stock Price Forecast - Intellectia AI
Eterna Therapeutics Updates Investor Presentation, Highlights Web Disclosure - TipRanks
Ernexa Therapeutics updates investor presentation, posts Exhibit 99.1 on website - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) furnishes new February 2026 investor presentation - Stock Titan
Ernexa Therapeutics (NASDAQ:ERNA) Trading Down 11.4% – Time to Sell? - Defense World
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - GlobeNewswire
Will Ernexa Therapeutics Inc. stock outperform value stocksQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Insider Stock Purchases: February 18, 2026 - Quiver Quantitative
Ernexa therapeutics ten percent owner Cherington buys $2m in stock By Investing.com - Investing.com India
Ernexa therapeutics ten percent owner Cherington buys $2m in stock - Investing.com
ERNA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will Ernexa Therapeutics Inc. outperform tech stocksJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
Can Ernexa Therapeutics Inc. continue delivering strong returnsQuarterly Trade Review & Capital Efficiency Focused Strategies - mfd.ru
Will Ernexa Therapeutics Inc. stock remain a Wall Street favoriteWeekly Market Outlook & Short-Term High Return Ideas - mfd.ru
Aug Shorts: Is Ernexa Therapeutics Inc a strong candidate for buy and holdTreasury Yields & Proven Capital Preservation Methods - baoquankhu1.vn
Will Ernexa Therapeutics Inc. stock benefit from green energy trendsTrade Volume Summary & Accurate Buy Signal Notifications - mfd.ru
Eterna Therapeutics Completes Public Offering to Bolster Capital - TipRanks
Ernexa Therapeutics Signs Multiple Financing Agreements - TradingView
Profit Review: Can Ernexa Therapeutics Inc. be recession proofWeekly Gains Report & Daily Momentum Trading Reports - mfd.ru
What hedge fund activity signals for Ernexa Therapeutics Inc. stockJuly 2025 PostEarnings & Target Return Focused Picks - mfd.ru
Total debt of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Ernexa Therapeutics prices $10.5 million public offering at $0.50 per share - Investing.com
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - The Manila Times
Ernexa Therapeutics Inc. Announces Pricing of $10.5 Million Public Offering of Common Stock and Warrants - Quiver Quantitative
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Street Watch: Is Ernexa Therapeutics Inc forming bullish engulfing patternsQuarterly Investment Review & Reliable Entry Point Alerts - baoquankhu1.vn
Valuation Update: Why is Ernexa Therapeutics Inc stock going up2025 Volume Leaders & Proven Capital Preservation Methods - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ernexa Therapeutics Advances toward First-in-Human Trial for Ovarian Cancer Following Successful Pre-IND Meeting with FDA - Quiver Quantitative
Ernexa Therapeutics Participates in Virtual Investor “What - GlobeNewswire
Japanese trade program selects Ernexa Therapeutics among elite biotech group - Investing.com Canada
Ernexa Therapeutics Selected for Japan Entry Acceleration Program to Advance Innovative Cell Therapies - Quiver Quantitative
Ernexa Therapeutics Selected as One of Only Ten Global - GlobeNewswire
Only 10 companies tapped for Japan’s JETRO program — Ernexa makes the cut - Stock Titan
New Highs: Can Ernexa Therapeutics Inc be recession proofEarnings Overview Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Can Ernexa Therapeutics Inc. be recession proofJuly 2025 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
Top movers in Tuesday's after hours session - ChartMill
Breakout Zone: Is RICK showing insider buyingRisk Management & Growth Focused Investment Plans - baoquankhu1.vn
Update Report: Is Ernexa Therapeutics Inc forming bullish engulfing patternsEarnings Recap Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Can Ernexa Therapeutics Inc continue delivering strong returnsPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Volume Report: What is TTGTs revenue forecastTrade Risk Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Ernexa Therapeutics (NASDAQ:ERNA) vs. Inotiv (NASDAQ:NOTV) Critical Review - Defense World
Market Recap: Can Ernexa Therapeutics Inc continue delivering strong returnsJuly 2025 PostEarnings & Low Risk High Reward Ideas - baoquankhu1.vn
Aug PostEarnings: Will Ernexa Therapeutics Inc. stock recover faster than peersMarket Performance Report & Weekly Top Performers Watchlists - Bộ Nội Vụ
Bull Run: How institutional buying supports Ernexa Therapeutics Inc stockJuly 2025 Trends & Low Drawdown Momentum Trade Ideas - Bộ Nội Vụ
Is Ernexa Therapeutics Inc. stock trading at a premium valuationJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
How Ernexa Therapeutics Inc. stock reacts to inflationary pressures2025 Price Momentum & Daily Price Action Insights - Улправда
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ernexa Therapeutics Inc Stock (ERNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Jun 09 '25 |
Buy |
0.10 |
21,241,163 |
2,221,826 |
41,659,743 |
| Cherington Charles | 10% Owner |
Apr 02 '25 |
Buy |
0.10 |
3,768,397 |
394,174 |
20,401,602 |
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):